131 related articles for article (PubMed ID: 18782650)
41. Vascular endothelial growth factor C stimulates progression of human gastric cancer via both autocrine and paracrine mechanisms.
Kodama M; Kitadai Y; Tanaka M; Kuwai T; Tanaka S; Oue N; Yasui W; Chayama K
Clin Cancer Res; 2008 Nov; 14(22):7205-14. PubMed ID: 19010837
[TBL] [Abstract][Full Text] [Related]
42. Construction of an immunotoxin with the pore forming protein StI and ior C5, a monoclonal antibody against a colon cancer cell line.
Tejuca M; Díaz I; Figueredo R; Roque L; Pazos F; Martínez D; Iznaga-Escobar N; Pérez R; Alvarez C; Lanio ME
Int Immunopharmacol; 2004 Jun; 4(6):731-44. PubMed ID: 15135315
[TBL] [Abstract][Full Text] [Related]
43. Adoptive immunotherapy of lung cancer with immobilized anti-TCRgammadelta antibody-expanded human gammadelta T-cells in peripheral blood.
Kang N; Zhou J; Zhang T; Wang L; Lu F; Cui Y; Cui L; He W
Cancer Biol Ther; 2009 Aug; 8(16):1540-9. PubMed ID: 19471115
[TBL] [Abstract][Full Text] [Related]
44. Effect of ex vivo-expanded γδ-T cells combined with galectin-1 antibody on the growth of human cervical cancer xenografts in SCID mice.
Li H; Wang Y; Zhou F
Clin Invest Med; 2010 Oct; 33(5):E280-9. PubMed ID: 20926034
[TBL] [Abstract][Full Text] [Related]
45. A new design immunotoxin for killing high-grade glioma U87 cells: from in vitro to in vivo.
Luqiu Z; Yiquan K; Gengqiang L; Yijing L; Xiaodan J; Yingqian C
J Immunotoxicol; 2012; 9(4):353-8. PubMed ID: 22458328
[TBL] [Abstract][Full Text] [Related]
46. Radiolabeled humanized anti-CD3 monoclonal antibody visilizumab for imaging human T-lymphocytes.
Malviya G; D'Alessandria C; Bonanno E; Vexler V; Massari R; Trotta C; Scopinaro F; Dierckx R; Signore A
J Nucl Med; 2009 Oct; 50(10):1683-91. PubMed ID: 19759100
[TBL] [Abstract][Full Text] [Related]
47. Voreloxin, formerly SNS-595, has potent activity against a broad panel of cancer cell lines and in vivo tumor models.
Hoch U; Lynch J; Sato Y; Kashimoto S; Kajikawa F; Furutani Y; Silverman JA
Cancer Chemother Pharmacol; 2009 Jun; 64(1):53-65. PubMed ID: 18931998
[TBL] [Abstract][Full Text] [Related]
48. Anti-tumoral effect of active immunotherapy in C57BL/6 mice using a recombinant human VEGF protein as antigen and three chemically unrelated adjuvants.
Morera Y; Bequet-Romero M; Ayala M; Lamdán H; Agger EM; Andersen P; Gavilondo JV
Angiogenesis; 2008; 11(4):381-93. PubMed ID: 19034678
[TBL] [Abstract][Full Text] [Related]
49. [Rhabdomyosarcoma lysis by T cells expressing a human autoantibody based chimeric receptor targeting the fetal acetylcholine receptors].
Gattenlöhner S
Verh Dtsch Ges Pathol; 2006; 90():264-76. PubMed ID: 17867605
[TBL] [Abstract][Full Text] [Related]
50. Small antibody mimetics comprising two complementarity-determining regions and a framework region for tumor targeting.
Qiu XQ; Wang H; Cai B; Wang LL; Yue ST
Nat Biotechnol; 2007 Aug; 25(8):921-9. PubMed ID: 17676038
[TBL] [Abstract][Full Text] [Related]
51. [Specific immune against pancreatic cancer induced by dendritic cells pulsed with mutant K-ras peptide].
Yang B; He Y; Sun DL; Zou Y; Qin XH; Huang BH
Zhonghua Yi Xue Za Zhi; 2008 Jul; 88(28):1956-60. PubMed ID: 19062734
[TBL] [Abstract][Full Text] [Related]
52. Antitumor activities of TEM8-Fc: an engineered antibody-like molecule targeting tumor endothelial marker 8.
Duan HF; Hu XW; Chen JL; Gao LH; Xi YY; Lu Y; Li JF; Zhao SR; Xu JJ; Chen HP; Chen W; Wu CT
J Natl Cancer Inst; 2007 Oct; 99(20):1551-5. PubMed ID: 17925540
[TBL] [Abstract][Full Text] [Related]
53. Affinity maturation of a humanized rat antibody for anti-RAGE therapy: comprehensive mutagenesis reveals a high level of mutational plasticity both inside and outside the complementarity-determining regions.
Finlay WJ; Cunningham O; Lambert MA; Darmanin-Sheehan A; Liu X; Fennell BJ; Mahon CM; Cummins E; Wade JM; O'Sullivan CM; Tan XY; Piche N; Pittman DD; Paulsen J; Tchistiakova L; Kodangattil S; Gill D; Hufton SE
J Mol Biol; 2009 May; 388(3):541-58. PubMed ID: 19285987
[TBL] [Abstract][Full Text] [Related]
54. Antigenic basis of diversity in the gammadelta T cell co-receptor WC1 family.
Chen C; Herzig CT; Telfer JC; Baldwin CL
Mol Immunol; 2009 Aug; 46(13):2565-75. PubMed ID: 19539374
[TBL] [Abstract][Full Text] [Related]
55. Anti-programmed death-1 synergizes with granulocyte macrophage colony-stimulating factor--secreting tumor cell immunotherapy providing therapeutic benefit to mice with established tumors.
Li B; VanRoey M; Wang C; Chen TH; Korman A; Jooss K
Clin Cancer Res; 2009 Mar; 15(5):1623-34. PubMed ID: 19208793
[TBL] [Abstract][Full Text] [Related]
56. Defective gammadelta T-cell function and granzyme B gene polymorphism in a cohort of newly diagnosed breast cancer patients.
Gaafar A; Aljurf MD; Al-Sulaiman A; Iqniebi A; Manogaran PS; Mohamed GE; Al-Sayed A; Alzahrani H; Alsharif F; Mohareb F; Ajarim D; Tabakhi A; Al-Hussein K
Exp Hematol; 2009 Jul; 37(7):838-48. PubMed ID: 19446661
[TBL] [Abstract][Full Text] [Related]
57. Inhibition of non-small cell lung cancer cell proliferation and tumor growth by vector-based small interfering RNAs targeting HER2/neu.
Ren XL; Xu YM; Bao W; Fu HJ; Wu CG; Zhao Y; Li ZK; Zhang J; Li SQ; Chen WQ; Wang T; Zhang R; Zhang LH; Qian GS; Chen SY; Jia LT; Yang AG
Cancer Lett; 2009 Aug; 281(2):134-43. PubMed ID: 19339104
[TBL] [Abstract][Full Text] [Related]
58. A key regulatory role of the transcription factor NFATc2 in bronchial adenocarcinoma via CD8+ T lymphocytes.
Maxeiner JH; Karwot R; Sauer K; Scholtes P; Boross I; Koslowski M; Türeci O; Wiewrodt R; Neurath MF; Lehr HA; Finotto S
Cancer Res; 2009 Apr; 69(7):3069-76. PubMed ID: 19318584
[TBL] [Abstract][Full Text] [Related]
59. Potent control of tumor growth by CEA/CD3-bispecific single-chain antibody constructs that are not competitively inhibited by soluble CEA.
Lutterbuese R; Raum T; Kischel R; Lutterbuese P; Schlereth B; Schaller E; Mangold S; Rau D; Meier P; Kiener PA; Mulgrew K; Oberst MD; Hammond SA; Baeuerle PA; Kufer P
J Immunother; 2009 May; 32(4):341-52. PubMed ID: 19342971
[TBL] [Abstract][Full Text] [Related]
60. Osteosarcoma cell line growth inhibition by zoledronate-stimulated effector cells.
Muraro M; Mereuta OM; Carraro F; Madon E; Fagioli F
Cell Immunol; 2007 Oct; 249(2):63-72. PubMed ID: 18163982
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]